Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 229 for:    EDN1

Cerebrovascular Reactivity in Alzheimer's Disease (VARAD-ET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03650816
Recruitment Status : Not yet recruiting
First Posted : August 29, 2018
Last Update Posted : August 20, 2019
Sponsor:
Collaborators:
Fondation Plan Alzheimer
Naturalia & Biologia
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The etiology of Alzheimer's disease (AD), the most common type of dementia, remains largely undefined and the early diagnostic and effective treatments are still not available. In addition to the neuropathological hallmarks, cerebrovascular dysfunction has been identified as an important component of AD. Using the experimental models, we showed that cerebrovascular reactivity (CVR), the ability of cerebral vessels to dilate or constrict in response to stimuli, is impaired very early in AD. We designed this trial to compare CVR to carbon dioxide (CVR CO2) in AD patients and in persons with subjective cognitive impairment (SCI), the cognitively healthy individuals which began to worry about worsening their memory, and to correlate CVR CO2 with AD markers in cerebrospinal fluid and the blood markers of endothelial function. We hypothesize that CVR represents a potential diagnostic/prognostic marker and an attractive target for the development of new therapeutics in AD.

Condition or disease Intervention/treatment
Alzheimer Disease Subjective Cognitive Impairment Other: Doppler ultrasonography Other: Biospecimen collection

Detailed Description:

The primary objective of this study is to determine, whether the measurement of CVR CO2 makes it possible to differentiate AD patients from control SCI subjects (subjects with a memory complaint but without cognitive impairment as assessed with neuropsychological tests).

We also pursue the following secondary objectives:

  • Establish correlations between cognitive level and CVR CO2 in the 2 groups: SCI and AD.
  • Investigate a correlation between CVR CO2 and AD markers in cerebrospinal fluid
  • Assess the correlation between cognitive function (Z score of neuropsychological tests) and CVR CO2.
  • Look for a correlation between CVR CO2 and plasma levels of markers of endothelial function: endothelin-1 (ET-1), big-ET-1, asymmetric dimethylarginine (ADMA) as well as plasma renin activity.

We plan to enroll a total of 24 male and/or female patients (> 18 years) with a diagnosis of AD (group AD) and 24 male and/or female SCI subjects (> 18 years) which came to our hospital for consultation about poor memory function.

Each patient will be informed on the study protocol during his / her regular follow-up visit at Broca hospital's day clinic. Informed consent/assent will be obtained from each subject or his/her representative prior to conducting any study related procedures.

Each study participant will make a total of two visits. The first (baseline) visit will be made to the Geriatric Department of the Broca hospital. At baseline visit, a complete medical history, physical examination, neurological examination, as well as the MRI and lumbar puncture data, if available, will be collected. A blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care. A medical appointment will be made at the Clinical Physiology Department of the Lariboisière Hospital for CVR CO2 measurement (visit 2).

The second and the final visit will take place approximately one month after the baseline visit. The CVR CO2 will be assessed using Doppler ultrasonography, as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position. Ten minutes after the end of the inhalation of the hypercapnic mixture, patients will receive a sublingual administration of a nitroglycerin spray (NTG 300 μg, Procter and Gamble Pharmaceuticals) and the carotid blood flow will be recorded between the 3rd and the 5th minute after NTG administration. In this way, the maximal blood flow obtained after endothelial-independent vasodilatation will be evaluated.

Changes in carotid blood flow (before and during hypercapnia) will be compared by a covariance analysis (variables known to interfere with CVR will be included as covariates). The analyses will be conducted considering the CVR CO2 variable in absolute values and relative values.

A multiple regression model will be used to test the hypothesis of a relationship between CVR CO2 and cognitive level (Z score of neuropsychological tests), CVR CO2 and AD markers in cerebrospinal fluid, and CVR CO2 and the plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity in the two groups: SCI and AD. Variables known to be cognitively related and known to be CVR related will be included in the model. The slopes of the regressions between CVR CO2 and the different parameters of interest will be compared between the two groups. Models taking into account each biomarker of interest separately and then a global model will be constructed.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 48 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 2 Months
Official Title: Evaluation of Cerebrovascular Reactivity in Alzheimer's Disease Patients : A Pilot Clinical Study
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : May 2, 2021
Estimated Study Completion Date : August 2, 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Alzheimer Disease

Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)

Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity

Other: Doppler ultrasonography
Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

Other: Biospecimen collection
Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity

Subjective Cognitive impairment

Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.

Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity

Other: Doppler ultrasonography
Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

Other: Biospecimen collection
Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity




Primary Outcome Measures :
  1. Cerebrovascular reactivity during the CO2 inhalation test in AD patients and control subjects (SCI) [ Time Frame: Up to 2 months ]

    Cerebrovascular reactivity during the CO2 inhalation test in AD patients and control subjects (SCI), determined from the measurements of blood flow in the internal and commun carotid arteries.

    Subjects will be screened and if applicable for the study will be scheduled for a Doppler ultrasonography. At the second visit they will complete Doppler ultrasonography measurements.



Secondary Outcome Measures :
  1. Correlation between cognitive status and différences in CVR CO2 [ Time Frame: Up to 2 months ]
    Cognitive status and its correlation with differences in CVR CO2 in both groups of patients after adjusting for age, sex, age, and factors associated with brain flow

  2. Correlation between cerebrospinal AD markers and CVR CO2 [ Time Frame: Up to 2 months ]
    Cerebrospinal AD markers and their relationship to CVR CO2 in AD patients and SCI controls after adjustment for age, gender, and factors associated with brain flow.

  3. Z score of neuropsychological tests and CVR CO2 [ Time Frame: Up to 2 months ]
    Cognitive function (Z score of neuropsychological tests) and its correlation with CVR CO2 in AD patients and SCI controls after adjustment for age, gender, and factors associated with brain flow.

  4. Plasma levels of ET-1, bigET-1, ADMA and their correlation with CVR CO2 [ Time Frame: Up to 2 months ]
    Plasma levels of ET-1, bigET-1, ADMA and their correlation with CVR CO2 in AD patients and SCI controls after adjustment for age, sex, and factors associated with brain flow.

  5. Plasma renin activity and CVR CO2. [ Time Frame: Up to 2 months ]
    Plasma renin activity and its correlation with alterations in CVR CO2.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
  1. Patients with Alzheimer's disease
  2. Patients with subjective cognitive impairment
Criteria

Inclusion Criteria:

  • Age 18 years and more
  • Alzheimer's disease as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA) or
  • Subjective cognitive impairment: subjects who consulted for cognitive complaint without cognitive impairment on neuropsychological tests defined by normal cognitive scores located between - 1.5 and + 1.5 standard deviations (σ) compared to the average of subjects in their reference group (same age, same socio-educational level) and normal performances according to daily life activities scores.

Exclusion Criteria:

  • Non-Alzheimer's dementia (vascular dementia, Lewy body dementia, fronto-temporal dementia, dementia linked to Parkinson's disease and other)
  • Other diseases that may interfere with cognitive performance evaluation (severe depression, epilepsy, Parkinson's disease, psychosis, bipolar syndrome)
  • Active smoking
  • Diabetes
  • Uncontrolled hypertension (PAS / PAD> 140/90 mmHg despite correctly dosed antihypertensive therapy)
  • Heart failure
  • Recent myocardial infarction
  • Stroke
  • Stenosis of the carotid commune or interne with plaque > 20%
  • Cerebrovascular lesions on MRI (major white matter lesions Fazekas 3,> 2 deficiencies and sequelae of cerebral infarction)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03650816


Contacts
Layout table for location contacts
Contact: Olivier HANON, MD PhD +33 1 44 08 33 81 olivier.hanon@aphp.fr
Contact: Bernard I LEVY, MD PhD + 33 1 45 26 21 98 bernanrd.levy@inserm.fr

Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Fondation Plan Alzheimer
Naturalia & Biologia
Investigators
Layout table for investigator information
Study Director: Florence FAVREL-FEUILLADE Clinical Research and Innovation Delegation

Additional Information:

Publications:
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03650816     History of Changes
Other Study ID Numbers: APHP180012
IDRCB 2018-A01950-55 ( Other Identifier: ANSM )
First Posted: August 29, 2018    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is not a plan to make IPD available.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Endothelin-1
Big-Endothelin-1
Alzheimer Disease
Subjective cognitive impairment
Cognitive Dysfunction
Neurodegenerative Diseases
Cerebrovascular reactivity
Doppler ultrasonography
Biomarker
ADMA
Renin
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders